Fabiano Poswar

Dr. Fabiano Poswar

Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
+1
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2018 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
Roberto GiuglianiRoberto Giugliani
Roberto Giugliani
LGLuciana Giugliani
Luciana Giugliani
Fabiano PoswarFabiano Poswar
Fabiano Poswar
KDKarina Carvalho Donis
Karina Carvalho Donis
ACAmauri Dalla Corte
Amauri Dalla Corte
William PardridgeWilliam Pardridge
William Pardridge
Mucopolysaccharidosis (MPS) Type I (MPSI) is caused by mutations in the gene encoding the lysosomal enzyme, α-L-iduronidase (IDUA), and a majority of patients present with severe neurodegeneration and cognitive impairment. Recombinant IDUA does not cross the blood-brain barrier (BBB). To enable BBB transport, IDUA was re-engineered as an IgG-IDUA fusion protein, valanafusp alpha, where the IgG domain targets the BBB human insulin receptor to enable transport of the enzyme into the brain. We report the results of a 52-week clinical trial on the safety and efficacy of valanafusp alpha in pediatric MPSI patients with cognitive impairment. In the phase I trial, 6 adults with attenuated MPSI were administered 0.3, 1, and 3 mg/kg doses of valanafusp alpha by intravenous (IV) infusion. In the phase II trial, 11 pediatric subjects, 2-15 years of age, were treated for 52 weeks with weekly IV infusions of valanafusp alpha at 1, 3, or 6 mg/kg. Assessments of adverse events, cognitive stabilization, and somatic stabilization were made. Outcomes at 52 weeks were compared to baseline. Drug related adverse events included infusion related reactions, with an incidence of 1.7%, and transient hypoglycemia, with an incidence of 6.4%. The pediatric subjects had CNS involvement with a mean enrollment Development Quotient (DQ) of 36.1±7.1. The DQ, and the cortical grey matter volume of brain, were stabilized by valanafusp alpha treatment. Somatic manifestations were stabilized, or improved, based on urinary glycosaminoglycan levels, hepatic and spleen volumes, and shoulder range of motion. Clinical evidence of the cognitive and somatic stabilization indicates that valanafusp alpha is transported into both the CNS and into peripheral organs due to its dual targeting mechanism via the insulin receptor and the mannose 6-phosphate receptor. This novel fusion protein offers a pharmacologic approach to the stabilization of cognitive function in MPSI. Clinical Trials.Gov, NCT03053089 . Retrospectively registered 9 February, 2017; Clinical Trials.Gov, NCT03071341 . Registered 6 March, 2017.

22 March 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
Francyne KubaskiFrancyne Kubaski
Francyne Kubaski
Fabiano PoswarFabiano Poswar
Fabiano Poswar
KMKristiane MICHELIN Michelin-Tirelli
Kristiane MICHELIN Michelin-Tirelli
MBMaira Graeff Burin
Maira Graeff Burin
DMDiana Málaga
Diana Málaga
Roberto GiuglianiRoberto Giugliani
Roberto Giugliani
The mucopolysaccharidoses (MPSs) include 11 different conditions caused by specific enzyme deficiencies in the degradation pathway of glycosaminoglycans (GAGs). Although most MPS types present increased levels of GAGs in tissues, including blood and urine, diagnosis is challenging as specific enzyme assays are needed for the correct diagnosis. Enzyme assays are usually performed in blood, with some samples (as leukocytes) providing a final diagnosis, while others (such as dried blood spots) still being considered as screening methods. The identification of variants in the specific genes that encode each MPS-related enzyme is helpful for diagnosis confirmation (when needed), carrier detection, genetic counseling, prenatal diagnosis (preferably in combination with enzyme assays) and phenotype prediction. Although the usual diagnostic flow in high-risk patients starts with the measurement of urinary GAGs, it continues with specific enzyme assays and is completed with mutation identification; there is a growing trend to have genotype-based investigations performed at the beginning of the investigation. In such cases, confirmation of pathogenicity of the variants identified should be confirmed by measurement of enzyme activity and/or identification and/or quantification of GAG species. As there is a growing number of countries performing newborn screening for MPS diseases, the investigation of a low enzyme activity by the measurement of GAG species concentration and identification of gene mutations in the same DBS sample is recommended before the suspicion of MPS is taken to the family. With specific therapies already available for most MPS patients, and with clinical trials in progress for many conditions, the specific diagnosis of MPS as early as possible is becoming increasingly necessary. In this review, we describe traditional and the most up to date diagnostic methods for mucopolysaccharidoses.

16 March 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
Francyne KubaskiFrancyne Kubaski
Francyne Kubaski
Fabiano PoswarFabiano Poswar
Fabiano Poswar
KMKristiane MICHELIN Michelin-Tirelli
Kristiane MICHELIN Michelin-Tirelli
UMUrsula Matte
Ursula Matte
DHDafne D. Horovitz
Dafne D. Horovitz
Roberto GiuglianiRoberto Giugliani
Roberto Giugliani
Mucopolysaccharidosis type I (MPS I) is caused by the deficiency of α-l-iduronidase, leading to the storage of dermatan and heparan sulfate. There is a broad phenotypical spectrum with the presence or absence of neurological impairment. The classical form is known as Hurler syndrome, the intermediate form as Hurler–Scheie, and the most attenuated form is known as Scheie syndrome. Phenotype seems to be largely influenced by genotype. Patients usually develop several somatic symptoms such as abdominal hernias, extensive dermal melanocytosis, thoracolumbar kyphosis odontoid dysplasia, arthropathy, coxa valga and genu valgum, coarse facial features, respiratory and cardiac impairment. The diagnosis is based on the quantification of α-l-iduronidase coupled with glycosaminoglycan analysis and gene sequencing. Guidelines for treatment recommend hematopoietic stem cell transplantation for young Hurler patients (usually at less than 30 months of age). Intravenous enzyme replacement is approved and is the standard of care for attenuated—Hurler–Scheie and Scheie—forms (without cognitive impairment) and for the late-diagnosed severe—Hurler—cases. Intrathecal enzyme replacement therapy is under evaluation, but it seems to be safe and effective. Other therapeutic approaches such as gene therapy, gene editing, stop codon read through, and therapy with small molecules are under development. Newborn screening is now allowing the early identification of MPS I patients, who can then be treated within their first days of life, potentially leading to a dramatic change in the disease’s progression. Supportive care is very important to improve quality of life and might include several surgeries throughout the life course.

1 January 2019 in Genetics and Molecular Biology
Verified
Journal Article
Open access
PDF file
Fabiano PoswarFabiano Poswar
Fabiano Poswar
Filippo VairoFilippo Vairo
Filippo Vairo
MBMaira Burin
Maira Burin
KMKristiane Michelin-Tirelli
Kristiane Michelin-Tirelli
ABAna Carolina Brusius-Facchin
Ana Carolina Brusius-Facchin
Roberto GiuglianiRoberto Giugliani
Roberto Giugliani
Lysosomal diseases (LDs), also known as lysosomal storage diseases (LSDs), are a heterogeneous group of conditions caused by defects in lysosomal function. LDs may result from deficiency of lysosomal hydrolases, membrane-associated transporters or other non-enzymatic proteins. Interest in the LD field is growing each year, as more conditions are, or will soon be treatable. In this article, we review the diagnosis of LDs, from clinical suspicion and screening tests to the identification of enzyme or protein deficiencies and molecular genetic diagnosis. We also cover the treatment approaches that are currently available or in development, including hematopoietic stem cell transplantation, enzyme replacement therapy, small molecules, and gene therapy.

1 June 2015 in Journal of Endodontics
Verified
Journal Article
Closed access
Fabiano PoswarFabiano Poswar
Fabiano Poswar
LFLucyana Conceição Farias
Lucyana Conceição Farias
CFCarlos Alberto de Carvalho Fraga
Carlos Alberto de Carvalho Fraga
WBWilson Bambirra
Wilson Bambirra
MBManoel Brito-Júnior
Manoel Brito-Júnior
André Luiz Sena GuimarãesAndré Luiz Sena Guimarães
André Luiz Sena Guimarães

1 January 2018 in The Lancet Child & Adolescent Health
Verified
Journal Article
Closed access
Roberto GiuglianiRoberto Giugliani
Roberto Giugliani
Filippo VairoFilippo Vairo
Filippo Vairo
FKFrancyne Kubaski
Francyne Kubaski
Fabiano PoswarFabiano Poswar
Fabiano Poswar
MRMariluce Riegel
Mariluce Riegel
JSJonas Alex Saute
Jonas Alex Saute